Subscribe to our Newsletters !!

    Hypoglycemia

    FDA supports new medication for therapy of adults with chronic kidney infection

    Today, the U.S. Food and Drug Administration accepted Farxiga (dapagliflozin) oral tablets to decrease the risk of kidney function decline, kidney failure, cardiovascular death and hospitalization for heart failure in adults with chronic kidney disease who are at risk of disease progression. Chronic kidney disease occurs when the kidneys are damaged and can’t filter blood